

## SAH-EZH2

Cat. No.:	HY-P2266
CAS No.:	1453222-26-8
Molecular Formula:	C <sub>155</sub> H <sub>256</sub> N <sub>48</sub> O <sub>40</sub>
Molecular Weight:	3431.99
Sequence Shortening:	Ac-FSSNR-((S)-2-(4'-pentenyl)Ala)-KIL-((S)-2-(4'-pentenyl)Ala)-RTQILNQEWKQRRIQPV (Covalent bridge: Ala6-Ala10)
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	SAH-EZH2, a stable EZH2 $\alpha$ -helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 <sup>[1]</sup> .
<b>In Vitro</b>	The selectivity of SAH-EZH2 activity is highlighted by the lack of a SAH-EZH2 effect on the H3K4, H3K9 and H3K36 methyl marks. MLL-AF9 leukemia cells, which are dependent on PRC2, undergo growth arrest and monocyte-macrophage differentiation upon treatment with SAH-EZH2, consistent with observed changes in expression of PRC2-regulated, lineage-specific marker genes <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Woojin Kim, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013 Oct;9(10):643-50.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA